10 High PE Stocks Insiders Are Buying

3. Exact Sciences Corporation (NASDAQ:EXAS)

Forward P/E ratio: 134.48

Exact Sciences Corporation (NASDAQ:EXAS) is a molecular diagnostics company specializing in cancer screening and precision oncology solutions. Its product portfolio includes a non-invasive stool DNA test for colorectal cancer, a provider of genomic insights for breast and colon cancer treatment decisions, and a comprehensive DNA and RNA-based test for therapy selection in advanced cancers. EXAS is also advancing blood-based tests for multi-cancer early detection, aiming to enhance early diagnosis and personalized treatment strategies.

Exact Sciences Corporation (NASDAQ:EXAS) delivered strong Q1 2025 results with core revenue growing 11% and adjusted EBITDA increasing by more than 60%. The company achieved significant commercial success with Screening revenue increasing 14% to $540 million, driven by growth in rescreens, care gap programs, and new ordering providers. Customer engagement improved substantially with field force engagement up more than 30% year-over-year and nearly 190,000 providers ordering during the first quarter, representing a 10% increase year-over-year.

Exact Sciences Corporation (NASDAQ:EXAS) made notable progress with new product launches, including Cologuard Plus, which demonstrates 95% cancer sensitivity and 94% specificity, resulting in a 40% reduction in false positives. The financial outlook was strengthened with increased guidance for total revenue and adjusted EBITDA guidance raised, and further reinforced by insider buying in the first months of the year. The company achieved breakeven free cash flow during the first quarter, marking a YoY improvement of $120 million, and expects strong full-year cash generation.